| Autor: |
Routley C; Research and Innovation, Asthma + Lung UK, London, UK., Walker S; Research and Innovation, Asthma + Lung UK, London, UK swalker@asthmaandlung.org.uk., Alton EW; National Heart and Lung Institute, Imperial College London, London, UK., Hall IP; Queen's Medical Centre, Nottingham, UK. |
| Jazyk: |
angličtina |
| Zdroj: |
Thorax [Thorax] 2024 Aug 19; Vol. 79 (9), pp. 809-810. Date of Electronic Publication: 2024 Aug 19. |
| DOI: |
10.1136/thorax-2024-221939 |
| Abstrakt: |
Competing Interests: Competing interests: Eric Alton Royalties or licenses: Royalties from Boehringer Ingelheim related to cystic fibrosis gene therapy programme. Consulting fees: Boehringer Ingelheim - payments made to EA and institution; AlveoGene - payments made to EA. Patents planned, issued or pending: multiple patents filed by Imperial College. Participation on a Data Safety Monitoring Board or Advisory Board: Boehringer Ingelheim Advisory Board - payments made to EA Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid. Founder Director, AlveoGeneStock or stock options AlveoGene shares - payments to EA. Sam Walker Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid co-Chair of Lung Research and Innovation Group (LRIG). Ian Hall: Grants or contracts from any entity. NIHR Senior Investigator Award - research grant to institution. Support for attending meetings and/or travel. Travel to AUKCAR meeting in Reading, 2024 - Expenses covered by Asthma+Lung UK Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid co-Chair of Lung Research and Innovation Group (LRIG). |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
